This 2018 review by Salzano et al. explores the therapeutic potential of growth hormone (GH) replacement in patients with chronic heart failure (CHF), a condition often associated with acquired GH deficiency. The authors outline how GH and its mediator IGF-1 influence myocardial function, vascular tone, and metabolic regulation. Although animal
This study examined the pharmacokinetics of growth hormone-releasing hormone (GHRH(1-29)-NH₂) and its ability to stimulate growth hormone (GH) secretion. The results showed that the administration of GHRH(1-29)-NH₂ significantly increased GH levels in participants, with a dose-dependent effect observed. This suggests that GHRH(1-29)-NH₂ could be a potential therapeutic agent for stimulating
This study evaluated the pharmacokinetics and efficacy of polyethylene glycol (PEG)-conjugated growth hormone-releasing hormone (GHRH) in healthy young and elderly subjects. The results showed that PEG-GHRH has an extended half-life compared to native GHRH, leading to prolonged GH secretion in both age groups. The GH response was dose-dependent, with higher
The study “Growth hormone administration stimulates energy expenditure and extrathyroidal conversion of thyroxine to triiodothyronine in a dose-dependent manner and suppresses circadian thyrotrophin levels: studies in GH-deficient adults” examines the effects of growth hormone (GH) therapy on metabolic processes and thyroid function in adults with GH deficiency. The findings indicate
